相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association of insulin resistance and β-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study
Tiange Wang et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Standards of medical care for type 2 diabetes in China 2019
Weiping Jia et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Jinhua Yan et al.
HEPATOLOGY (2019)
Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and -Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis
Jaehyun Bae et al.
DIABETES THERAPY (2019)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2018 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2018)
Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors
Stefano Del Prato et al.
DIABETES OBESITY & METABOLISM (2018)
Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Koichi Yabiku et al.
CLINICAL THERAPEUTICS (2017)
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Jeffrey Cui et al.
JOURNAL OF HEPATOLOGY (2016)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus
Linong Ji et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan: the ERA JUMP study
Vasudha Ahuja et al.
DIABETOLOGIA (2015)
Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes
Yan Bi et al.
ACTA DIABETOLOGICA (2014)
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Liang-Kung Chen et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2014)
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Jie Hong et al.
DIABETES CARE (2013)
Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response A systematic review and meta-analysis
Keiichi Kodama et al.
DIABETES CARE (2013)
EFFICACY AND SAFETY OF ADDING PIOGLITAZONE OR SITAGLIPTIN TO PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED WITH METFORMIN AND A SULFONYLUREA
Sung-Chen Liu et al.
ENDOCRINE PRACTICE (2013)
Prevalence and Control of Diabetes in Chinese Adults
Yu Xu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Effects of Pioglitazone on Visceral Fat Metabolic Activity in Impaired Glucose Tolerance or Type 2 Diabetes Mellitus
Norihiro Kodama et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Programme and policy options for preventing obesity in China
H. Wang et al.
OBESITY REVIEWS (2013)
Impact of Three Oral Antidiabetic Drugs on Markers of β-Cell Function in Patients with Type 2 Diabetes: A Meta-Analysis
Jin Lu et al.
PLOS ONE (2013)
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
An-Wen Chan et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial
Shalini Chawla et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2013)
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
David Russell-Jones et al.
DIABETES CARE (2012)
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Takamasa Ohki et al.
SCIENTIFIC WORLD JOURNAL (2012)
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*
Wenying Yang et al.
JOURNAL OF DIABETES (2012)
SITAGLIPTIN COMPARED WITH THIAZOLIDINEDIONES AS A THIRD-LINE ORAL ANTIHYPERGLYCEMIC AGENT IN TYPE 2 DIABETES MELLITUS
Stanley H. Hsia et al.
ENDOCRINE PRACTICE (2011)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
Viswanathan Mohan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Pancreatic fat content and β-cell function in men with and without type 2 diabetes
Maarten E. Tushuizen et al.
DIABETES CARE (2007)
Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus
Tetsuya Teranishi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Skeletal muscle mass and aging: Regional and whole-body measurement methods
RC Lee et al.
CANADIAN JOURNAL OF APPLIED PHYSIOLOGY-REVUE CANADIENNE DE PHYSIOLOGIE APPLIQUEE (2001)
分享论文
